Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors ; volume:25 ; number:1 ; day:24 ; month:1 ; year:2024 ; pages:1-13 ; date:12.2024
BMC immunology ; 25, Heft 1 (24.1.2024), 1-13, 12.2024
- Urheber
-
Wang, Jingting
Ma, Yan
Lin, Haishan
Wang, Jing
Cao, Bangwei
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12865-024-00599-y
- URN
-
urn:nbn:de:101:1-2024040509421226235877
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Jingting
- Ma, Yan
- Lin, Haishan
- Wang, Jing
- Cao, Bangwei
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
Managing immune-related adverse events in oncology
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
Managing immune-related adverse events in oncology
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors
Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Intrahepatic Bile Duct Injury as a Hepatic Immune-Related Adverse Event after Immune-Checkpoint Inhibitor Treatment
Managing immune-related adverse events in oncology
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events